Ewha Med J.  2016 Jan;39(1):14-16. 10.12771/emj.2016.39.1.14.

Paroxetine-induced Hypoglycemia in Type 2 Diabetic Patient

• Han S
• Park HS
• Lee YH
• Lee BW
• Kang ES
• Cha BS

• KMID: 2152752
• DOI: http://doi.org/10.12771/emj.2016.39.1.14

Abstract

Selective serotonin reuptake inhibitors are commonly prescribed drugs for the treatment of depression in the patients with diabetes. Here, we report a case of paroxetineinduced severe recurrent hypoglycemia that developed in a 35-year-old woman with poorly controlled type 2 diabetes complicated by diabetic nephropathy and neuropathy. She discontinued her daily insulin therapy 2 months after the introduction of paroxetine, but hypoglycemic events were sustained. After discontinuation of paroxetine, no more hypoglycemic events occurred.

Keyword

Serotonin uptake inhibitor; Paroxetine; hypoglycemia; Type 2 diabetes mellitus

MeSH Terms

Adult
Depression
Diabetes Mellitus, Type 2
Diabetic Nephropathies
Female
Humans
Hypoglycemia*
Insulin
Paroxetine
Serotonin Uptake Inhibitors
Insulin
Paroxetine
Serotonin Uptake Inhibitors

Figure

• 

  Fig. 1 72-hour continuous glucose monitoring. Hypoglycemic episodes occur paroxysmally without insulin therapy. The lowest glucose level is 31 mg/dL.

Reference

1. Ali S, Stone MA, Peters JL, Davies MJ, Khunti K. The prevalence of co-morbid depression in adults with Type 2 diabetes: a systematic review and meta-analysis. Diabet Med. 2006; 23:1165–1173.

2. Deeg MA, Lipkin EW. Hypoglycemia associated with the use of fluoxetine. West J Med. 1996; 164:262–263.

3. Maheux P, Ducros F, Bourque J, Garon J, Chiasson JL. Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. Int J Obes Relat Metab Disord. 1997; 21:97–102.

4. Gomez R, Huber J, Tombini G, Barros HM. Acute effect of different antidepressants on glycemia in diabetic and non-diabetic rats. Braz J Med Biol Res. 2001; 34:57–64.

5. Potter van Loon BJ, Radder JK, Frolich M, Krans HM, Zwinderman AH, Meinders AE. Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals. Int J Obes Relat Metab Disord. 1992; 16:79–85.

6. Preskorn SH, Magnus RD. Inhibition of hepatic P-450 isoenzymes by serotonin selective reuptake inhibitors: in vitro and in vivo findings and their implications for patient care. Psychopharmacol Bull. 1994; 30:251–259.

7. Biagetti B, Corcoy R. Hypoglycemia associated with fluoxetine treatment in a patient with type 1 diabetes. World J Clin Cases. 2013; 1:169–171.

8. O'Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med. 1994; 11:105–110.

9. Potter van Loon BJ, Radder JK, Frolich M, Krans HM, Zwinderman AH, Meinders AE. Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients. Int J Obes Relat Metab Disord. 1992; 16:Suppl 4. S55–S61.

10. Sawka AM, Burgart V, Zimmerman D. Loss of awareness of hypoglycemia temporally associated with selective serotonin reuptake inhibitors. Diabetes Care. 2001; 24:1845–1846.

11. Weber-Hamann B, Gilles M, Lederbogen F, Heuser I, Deuschle M. Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. J Clin Psychiatry. 2006; 67:1856–1861.

12. Kesim M, Duman EN, Kadioglu M, Ulku C, Muci E, Kalyoncu NI, et al. Antinociceptive effects of fluoxetine and paroxetine with their related actions on glycemia in mice. Neuro Endocrinol Lett. 2006; 27:281–287.

13. Alsahli M, Gerich JE. Hypoglycemia, chronic kidney disease, and diabetes mellitus. Mayo Clin Proc. 2014; 89:1564–1571.

14. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003; 26:1553–1579.

15. Yun JS, Kim JH, Song KH, Ahn YB, Yoon KH, Yoo KD, et al. Cardiovascular autonomic dysfunction predicts severe hypoglycemia in patients with type 2 diabetes: a 10-year follow-up study. Diabetes Care. 2014; 37:235–241.